The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL OMB 3235-Number: 0076 Estimated average burden hours per

response:

4.00

1. Issuer's Identity

**CIK (Filer ID Number)** 

**Previous** Names

None

**Entity Type** 

Limited Liability Company

0001095435

**BONTAN CORP INC** Name of Issuer

DEALCHECK COM INC

Limited Partnership

X Corporation

PORTAGE BIOTECH INC.

Jurisdiction of **Incorporation/Organization** 

ONTARIO, CANADA

General Partnership **Business Trust** 

Other (Specify)

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

PORTAGE BIOTECH INC.

**Street Address 1** 

**Street Address 2** 

61 Wilton Road

c/o Portage Development Services Inc. ZIP/PostalCode State/Province/Country **Phone Number of Issuer** 

City

**CONNECTICUT** 06880 416-737-7600

3. Related Persons

**Last Name** 

**First Name** 

Middle Name

Walters

Westport

Ian

В.

**Street Address 1** 

**Street Address 2** 

61 Wilton Road

c/o Portage Development Services

City

**Relationship:** X Executive Officer X Director Promoter

Inc. State/Province/Country

ZIP/PostalCode

Westport

CONNECTICUT

06880

Clarification of Response (if Necessary):

Chief Executive Officer and Director

L	ast Name	First Name	Middle Name

Shaw Allan

> **Street Address 1 Street Address 2**

> > c/o Portage Development Services

61 Wilton Road Inc.

> City State/Province/Country ZIP/PostalCode

Westport **CONNECTICUT** 06880 **Relationship:** X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Financial Officer

Last Name First Name Middle Name

Kramer Robert

Street Address 1 Street Address 2

61 Wilton Road c/o Portage Development Services

Inc.

City State/Province/Country ZIP/PostalCode

Westport CONNECTICUT 06880

**Relationship:** X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Scientific Officer

Last Name First Name Middle Name

Bailey Gregory

Street Address 1 Street Address 2

61 Wilton Road c/o Portage Development Services

Inc.

City State/Province/Country ZIP/PostalCode

Westport CONNECTICUT 06880

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Director, Chairman of the Board

Last Name First Name Middle Name

Glassman Robert

Street Address 1 Street Address 2

61 Wilton Road c/o Portage Development Services

Inc.

City State/Province/Country ZIP/PostalCode

Westport CONNECTICUT 06880

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Mintz

Street Address 1 Street Address 2

61 Wilton Road c/o Portage Development Services

Inc.

City State/Province/Country ZIP/PostalCode

Westport CONNECTICUT 06880

Steven

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Kozick Linda M.

Street Address 1 Street Address 2

c/o Portage Development Services

61 Wilton Road Inc.

City State/Province/Country ZIP/PostalCode

Westport CONNECTICUT 06880

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Mellon James

Street Address 1 Street Address 2

61 Wilton Road c/o Portage Development Services

Inc.

City State/Province/Country ZIP/PostalCode

Westport CONNECTICUT 06880

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Simon Mark

Street Address 1 Street Address 2

c/o Portage Development Services

61 Wilton Road Inc.

City State/Province/Country ZIP/PostalCode

Westport CONNECTICUT 06880

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing

Banking & Financial Services Biotechnology Restaurants
Commercial Banking Health Insurance Technology

Insurance Hospitals & Physicians Computers

Investment Banking X Pharmaceuticals Telecommunications

Pooled Investment Fund Other Health Care Other Technology
Is the issuer registered as Manufacturing Travel

Is the issuer registered as Manufacturing Travel an investment company under Real Estate Airlines &

the Investment Company
Act of 1940?

Real Estate

Real Estate

Airlines & Airports

Commercial

Lodging & Conventions

Yes No Construction Tourism & Travel Services

Other Banking & Financial Services REITS & Finance Other Travel

Business Services Residential Other

Energy Other Real Estate

Energy Conservation

Environmental Services

Oil & Gas

Coal Mining
Electric Utilities

Other Energy

5. Issuer Size

Revenue Range OR Aggregate Net Asset Value Range

No Revenues No Aggregate Net Asset Value

\$1 - \$1,000,000 \$1 - \$5,000,000

\$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000

\$5,000,001 - \$25,000,001 - \$50,000,000

\$25,000,000 \$25,000,000

\$25,000,001 -\$100,000,000 \$50,000,001 - \$100,000,000

Over \$100,000,000

X Decline to Disclose
Not Applicable

Over \$100,000,000

Decline to Disclose
Not Applicable

# 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Sect		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)	
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)	
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)	
Rule 504 (b)(1)(iii) X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)	
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)	
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)	
	Section $3(c)(7)$		

Section 3(c)(/)

# 7. Type of Filing

X New Notice Date of First Sale 2022-07-18 First Sale Yet to Occur Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity Pooled Investment Fund Interests

Debt Tenant-in-Common Securities

Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities

Security to be Acquired Upon Exercise of Option, Warrant or

Other Right to Acquire Security

Other (describe)

## 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Clarification of Response (if Necessary):

In exchange for the remaining equity in iOx Therapeutics Ltd., certain iOx shareholders received 1,070,000 ordinary shares of the Issuer and a contingent right to receive \$25,000,000 of the Issuer's shares or cash upon achievement of a certain milestone.

X None

### 11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

## 12. Sales Compensation

Recipient CRD Number X None

(Associated) Broker or Dealer X None (Associated) Broker or Dealer CRD Number

Street Address 1 Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation (select all that apply) Check "All States" or check individual States

All States

Foreign/non-US

# 13. Offering and Sales Amounts

Total Offering Amount \$34,640,700 USD or Indefinite

Total Amount Sold \$34,640,700 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

Value of the 1,070,000 shares issued is based on the closing price for the shares on the last trading day prior to issuance. Amounts include \$25,000,000 of shares issuable upon achievement of the milestone which may be paid in cash at the Issuer's option.

#### 14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

## 15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
PORTAGE BIOTECH INC.	/s/ Allan Shaw	Allan Shaw	Chief Financial Officer	2022-07-29

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.